PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
17.94
+0.94 (5.53%)
Jun 26, 2025, 4:00 PM - Market closed
PureTech Health Revenue
In the year 2024, PureTech Health had annual revenue of $4.83M with 44.98% growth. PureTech Health had revenue of $4.54M in the half year ending December 31, 2024, a decrease of -47.13%.
Revenue (ttm)
$4.83M
Revenue Growth
+44.98%
P/S Ratio
87.74
Revenue / Employee
$86,214
Employees
56
Market Cap
423.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
PRTC News
- 10 days ago - PureTech Health: Results of Annual General Meeting - Business Wire
- 5 weeks ago - PureTech to Present at the Jefferies Global Healthcare Conference - Business Wire
- 6 weeks ago - PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF) - Business Wire
- 2 months ago - PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference - Business Wire
- 2 months ago - PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - PureTech Announces Annual Results for Year Ended December 31, 2024 - Business Wire
- 2 months ago - PureTech Health: Notice of Results - Business Wire
- 2 months ago - PureTech Appoints Peel Hunt as Joint UK Corporate Broker - Business Wire